Future research should investigate whether combining SGLT2 inhibitors with other pharmacological agents, such as GLP-1 receptor agonists or PPAR agonists, yields additive benefits in reducing hepatic fat and preventing MASLD progression. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.